BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1904892)

  • 1. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy.
    Wyse DG; Hallstrom A; McBride R; Cohen JD; Steinberg JS; Mahmarian J
    J Am Coll Cardiol; 1991 Jul; 18(1):20-8. PubMed ID: 1904892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.
    Epstein AE; Bigger JT; Wyse DG; Romhilt DW; Reynolds-Haertle RA; Hallstrom AP
    J Am Coll Cardiol; 1991 Jul; 18(1):14-9. PubMed ID: 1904891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
    Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
    Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.
    Capone RJ; Pawitan Y; el-Sherif N; Geraci TS; Handshaw K; Morganroth J; Schlant RC; Waldo AL
    J Am Coll Cardiol; 1991 Nov; 18(6):1434-8. PubMed ID: 1939943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.
    Greene HL; Roden DM; Katz RJ; Woosley RL; Salerno DM; Henthorn RW
    J Am Coll Cardiol; 1992 Apr; 19(5):894-8. PubMed ID: 1552108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
    Epstein AE; Hallstrom AP; Rogers WJ; Liebson PR; Seals AA; Anderson JL; Cohen JD; Capone RJ; Wyse DG
    JAMA; 1993 Nov; 270(20):2451-5. PubMed ID: 8230622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.
    Akiyama T; Pawitan Y; Campbell WB; Papa L; Barker AH; Rubbert P; Friedman L; Keller M; Josephson RA
    J Am Geriatr Soc; 1992 Jul; 40(7):666-72. PubMed ID: 1607582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
    Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
    N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
    Am J Cardiol; 1988 Apr; 61(10):704-13. PubMed ID: 2451414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
    Peters RW; Mitchell LB; Brooks MM; Echt DS; Barker AH; Capone R; Liebson PR; Greene HL
    J Am Coll Cardiol; 1994 Feb; 23(2):283-9. PubMed ID: 8294678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA; Gillette PC; Benson DW
    J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encainide--an updated safety profile.
    Thomis JA
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():585-94. PubMed ID: 2125837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
    Akiyama T; Pawitan Y; Greenberg H; Kuo CS; Reynolds-Haertle RA
    Am J Cardiol; 1991 Dec; 68(17):1551-5. PubMed ID: 1720917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Akhtar M; Breithardt G; Camm AJ; Coumel P; Janse MJ; Lazzara R; Myerburg RJ; Schwartz PJ; Waldo AL; Wellens HJ
    Circulation; 1990 Mar; 81(3):1123-7. PubMed ID: 1689621
    [No Abstract]   [Full Text] [Related]  

  • 18. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications.
    Pratt CM; Moye LA
    Am J Cardiol; 1990 Jan; 65(4):20B-29B. PubMed ID: 2105049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAST and beyond. Implications of the cardiac arrhythmia suppression trials. By the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Eur Heart J; 1990 Mar; 11(3):194-9. PubMed ID: 2108031
    [No Abstract]   [Full Text] [Related]  

  • 20. Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.
    Anderson JL; Hallstrom AP; Griffith LS; Ledingham RB; Reiffel JA; Yusuf S; Barker AH; Fowles RE; Young JB
    Circulation; 1989 Mar; 79(3):610-9. PubMed ID: 2465099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.